Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 298Carcinoma, Non-Small-Cell Lung 226Neoplasms 195Prostatic Neoplasms 163Multiple Myeloma 140Neoplasm Metastasis 117Melanoma 113Colorectal Neoplasms 108Leukemia, Myeloid, Acute 107Lung Neoplasms 98Lymphoma 97Ovarian Neoplasms 87Squamous Cell Carcinoma of Head and Neck 77Lymphoma, Non-Hodgkin 73Leukemia, Lymphocytic, Chronic, B-Cell 72Myelodysplastic Syndromes 65Triple Negative Breast Neoplasms 64Pancreatic Neoplasms 64Hematologic Neoplasms 60Parkinson Disease 4, Autosomal Dominant Lewy Body 59Head and Neck Neoplasms 59Glioblastoma 57Recurrence 56Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Leukemia 56Sarcoma 49Brain Neoplasms 49Lymphoma, Large B-Cell, Diffuse 48Carcinoma, Hepatocellular 47Lymphoma, Follicular 46

Interventions

tirabrutinib 1obinutuzumab 1idelalisib 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × B-cell Malignancies × 1 year × Clear all
NCT02457598 2025-06-17

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Gilead Sciences

Phase 1 Terminated
203 enrolled 43 charts
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡